Intrommune Therapeutics To Present A New Form Of Allergy Treatment At The 2024 American Academy Of Allergy, Asthma & Immunology (AAAAI) Annual Meeting New study is the first to evaluate Oral Mucosal Immunotherapy (OMIT) for the treatment of food allergy

Research Presentations at the 2021 Annual AAAAI Meeting Highlight Limitations of Current Food Allergy Treatments and Further Validates Intrommune Therapeutics’ Approach NEW YORK, March 12, 2021 (GLOBE NEWSWIRE) -- The clinical and scientific team of Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing patient-friendly treatments...

The asthma & allergy friendly® Certification Program Showcases Its Certified Products and Services to Thousands of Allergist, Immunologists, and Healthcare Professionals from Around the World WASHINGTON, DC., March 02, 2018 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) and Allergy Standards Limited (ASL) announced today that the asthma & allergy friendly®...